Global DNA Repair Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global DNA Repair Drugs Market Research Report 2024
DNA damage leads to the incorporation of defects and aberrations in the genome that often result in functional mutations. When these mutations occur in genes coding for vital proteins and/or enzymes, it leads to the development of genetic diseases. However, our biological system is equipped with a robust repair mechanism capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body’s innate DNA repair mechanism and aid in the treatment of diseases associated with genetic aberrations.
According to Mr Accuracy reports’s new survey, global DNA Repair Drugs market is projected to reach US$ 1993.3 million in 2034, increasing from US$ 593.6 million in 2024, with the CAGR of 18.4% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole DNA Repair Drugs market research.
Key manufacturers engaged in the DNA Repair Drugs industry include 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group and GlaxoSmithKline, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of DNA Repair Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole DNA Repair Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global DNA Repair Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
4SC AG
ARCAGY/ GINECO GROUP
Bristol Myers Squibb
British Columbia Cancer Agency
Cambridge University Hospitals NHS Foundation Trust
Genentech
Georgetown University
German Breast Group
GlaxoSmithKline
Jiangsu Hengrui Medicine
Johnson & Johnson
Jonsson Comprehensive Cancer Center
Karyopharm Therapeutics
KuDOS Pharmaceuticals
National Health Service
National Institutes of Health
Tesaro
Segment by Type
PARP Inhibitors
Other
Oncological
Stroke
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The DNA Repair Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global DNA Repair Drugs market is projected to reach US$ 1993.3 million in 2034, increasing from US$ 593.6 million in 2024, with the CAGR of 18.4% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole DNA Repair Drugs market research.
Key manufacturers engaged in the DNA Repair Drugs industry include 4SC AG, ARCAGY/ GINECO GROUP, Bristol Myers Squibb, British Columbia Cancer Agency, Cambridge University Hospitals NHS Foundation Trust, Genentech, Georgetown University, German Breast Group and GlaxoSmithKline, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of DNA Repair Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole DNA Repair Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global DNA Repair Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
4SC AG
ARCAGY/ GINECO GROUP
Bristol Myers Squibb
British Columbia Cancer Agency
Cambridge University Hospitals NHS Foundation Trust
Genentech
Georgetown University
German Breast Group
GlaxoSmithKline
Jiangsu Hengrui Medicine
Johnson & Johnson
Jonsson Comprehensive Cancer Center
Karyopharm Therapeutics
KuDOS Pharmaceuticals
National Health Service
National Institutes of Health
Tesaro
Segment by Type
PARP Inhibitors
Other
Segment by Application
Oncological
Stroke
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The DNA Repair Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source